跳轉至內容
Merck
全部照片(1)

Key Documents

M2699

Sigma-Aldrich

马立马司他

≥98% (HPLC), solid, MMP inhibitor

同義詞:

BB2516, (2S,3R)-N4- [(1S)-2,2-二甲基-1- [(甲氨基)羰基] 丙基]-N1,2-二羟基-3-(2-甲基丙基)丁二酰胺

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C15H29N3O5
CAS號碼:
分子量::
331.41
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

product name

马立马司他, ≥98% (HPLC)

品質等級

化驗

≥98% (HPLC)

形狀

solid

溶解度

DMSO: ≥20 mg/mL

運輸包裝

wet ice

儲存溫度

−20°C

SMILES 字串

CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C

InChI

1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1

InChI 密鑰

OCSMOTCMPXTDND-OUAUKWLOSA-N

基因資訊

應用

Marimastat已用作下列抑制剂:
  • 金属蛋白酶2/9 (MMP2/9),以研究其对小鼠运动介导的白细胞介素-6 (IL-6)释放的影响
  • 金属蛋白酶,测定铜绿假单胞菌培养物中的蛋白酶活性
  • 金属蛋白酶10 (MMP10),研究其对结合MMP10的单克隆抗体H3的影响

生化/生理作用

Marimastat 是一种广谱基质金属蛋白酶 (MMP) 抑制剂

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Vincent E de Meijer et al.
PloS one, 5(6), e11256-e11256 (2010-07-02)
Liver fibrosis is characterized by excessive synthesis of extracellular matrix proteins, which prevails over their enzymatic degradation, primarily by matrix metalloproteinases (MMPs). The effect of pharmacological MMP inhibition on fibrogenesis, however, is largely unexplored. Inflammation is considered a prerequisite and
Aura D Urribarri et al.
Gut, 63(10), 1658-1667 (2014-01-18)
Polycystic liver diseases (PCLDs) are genetic disorders characterised by progressive bile duct dilatation and/or cyst development. Their pathogenesis is a consequence of hyperproliferation, hypersecretion and microRNA alterations in cholangiocytes. Here we evaluate the role of matrix metalloproteases (MMPs) in the
Timothy W Failes et al.
Chemistry (Weinheim an der Bergstrasse, Germany), 13(10), 2974-2982 (2006-12-16)
We report a potential means of selectively delivering matrix metalloproteinase (MMP) inhibitors to target tumour sites by use of a bioreductively activated Co(III) carrier system. The carrier, comprising a Co(III) complex of the tripodal ligand tris(methylpyridyl)amine (tpa), was investigated with
Victor A Levin et al.
Journal of neuro-oncology, 78(3), 295-302 (2006-04-26)
Because raised matrix metalloprotease (MMP) levels are associated with glioma invasion and angiogenesis, we tested the efficacy of marimastat (MT) an orally active drug that can reduce MMP levels, in patients with gliomas. A total of 162 patients with intracranial
M Ohshima et al.
Journal of dental research, 89(11), 1315-1321 (2010-08-27)
The underlying mechanism and the therapeutic regimen for the transition of reversible gingivitis to irreversible periodontitis are unclear. Since transforming growth factor (TGF)-β has been implicated in differentially regulated gene expression in gingival fibroblasts, we hypothesized that TGF-β signaling is

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務